

MATERIAL SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY

Material	NIKKI™ (Drospirenone and Ethinyl Estradiol Tablets USP) 3 mg/0.02 mg
Manufacturer	Lupin Limited Pithampur (M.P.) - 454 775 INDIA
Distributor	Lupin Pharmaceuticals, Inc. Harborplace Tower, 21 st Floor 111, South Calvert Street Baltimore, MD 21202 United States Tel. 001-410-576-2000 Fax. 001-410-576-2221

2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients	CAS
Drospirenone	67392-87-4
Ethinyl Estradiol USP	57-63-6

3. HAZARD IDENTIFICATION

Fire and Explosion	Expected to be non-combustible
Health	Do not prescribe Nikki™ to women who are known to have the following: <ul style="list-style-type: none">• Renal impairment• Adrenal insufficiency• A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:<ul style="list-style-type: none">• Smoke, if over age 35.• Have deep vein thrombosis or pulmonary embolism, now or in the past Have cerebrovascular disease [Have coronary artery disease.• Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation).

- Have inherited or acquired hypercoagulopathies.
- Have uncontrolled hypertension.
- Have diabetes mellitus with vascular disease.
- Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35.
- Undiagnosed abnormal uterine bleeding.
- Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past.
- Liver tumors, benign or malignant, or liver disease.
- Pregnancy, because there is no reason to use COCs during pregnancy.

Environment

No information is available about the potential of this product to produce adverse environmental effects.

4. FIRST AID MEASURE

Ingestion

If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.

Inhalation

Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

Skin Contact

Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

Eye Contact

Flush eyes with plenty of water. Get medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment

Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.

Overdosage

There have been no reports of serious ill effects from overdose, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.

Drospirenone is a spironolactone analogue which has antiminerlocorticoid properties. Serum concentration of potassium and sodium, and evidence of metabolic acidosis, should be monitored in cases of overdose.

5. FIRE FIGHTING MEASURE

Fire and Explosion Hazards	Assume that this product is capable of sustaining combustion.
Extinguishing Media	Water spray, carbon dioxide, dry chemical powder or appropriate foam.
Special Firefighting Procedures	For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters.
Hazardous Combustion Products	Hazardous combustion or decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions	Wear protective clothing and equipment consistent with the degree of hazard.
Environmental Precautions	For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.
Clean-up Methods	Collect and place it in a suitable, properly labeled container for recovery or disposal.

7. HANDLING AND STORAGE

Handling	No special control measures required for the normal handling of this product.
Storage	Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [See USP Controlled Room Temperature].

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical Form

NIKKI™ (drospirenone and ethinyl estradiol tablets USP), 3 mg/0.02 mg is available in a wallet (NDC 68180-886-11) packed in a pouch (NDC 68180-886-11). Such three pouches are packaged in a carton (NDC 68180-886-13).

Each wallet pack (28 film-coated tablets) contains in the following order:

- 24 active pink, round, biconvex, film-coated tablets, debossed with "LU" on one side and "K31" on the other side each containing 3 mg drospirenone and 0.02 mg ethinyl estradiol
- 4 inert white to off-white round, biconvex film-coated tablets debossed with "K33" on one side and "LU" on the other side.

10. STABILITY AND REACTIVITY

Stable under recommended storage conditions.

11. TOXICOLOGICAL INFORMATION

Carcinogenesis, Mutagenesis, Impairment of Fertility

In a 24 month oral carcinogenicity study in mice dosed with 10 mg/kg/day drospirenone alone or 1 + 0.01, 3 + 0.03 and 10 + 0.1 mg/kg/day of drospirenone and ethinyl estradiol, 0.1 to 2 times the exposure (AUC of drospirenone) of women taking a contraceptive dose, there was an increase in carcinomas of the harderian gland in the group that received the high dose of drospirenone alone. In a similar study in rats given 10 mg/kg/day drospirenone alone or 0.3 + 0.003, 3 + 0.03 and 10 + 0.1 mg/kg/day drospirenone and ethinyl estradiol, 0.8 to 10 times the exposure of women taking a contraceptive dose, there was an increased incidence of benign and total (benign and malignant) adrenal gland pheochromocytomas in the group receiving the high dose of drospirenone. Mutagenesis studies for drospirenone were conducted *in vivo* and *in vitro* and no evidence of mutagenic activity was observed.

12. ECOLOGICAL INFORMATION

No relevant studies identified.

13. DISPOSAL CONSIDERATION

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

14. TRANSPORT INFORMATION

IATA/ICAO - Not Regulated

IATA Proper shipping Name	:	N/A
IATA UN/ID No	:	N/A
IATA Hazard Class	:	N/A
IATA Packaging Group	:	N/A
IATA Label	:	N/A

IMDG - Not Regulated

IMDG Proper shipping Name	:	N/A
IMDG UN/ID No	:	N/A
IMDG Hazard Class	:	N/A
IMDG Flash Point	:	N/A
IMDG Label	:	N/A

DOT - Not Regulated

DOT Proper shipping Name	:	N/A
DOT UN/ID No	:	N/A
DOT Hazard Class	:	N/A
DOT Flash Point	:	N/A
DOT Packing Group	:	N/A
DOT Label	:	N/A

15. REGULATORY INFORMATION

This Section Contains Information relevant to compliance with other Federal and/or state laws.

16. OTHER INFORMATION

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this MSDS.